Sorafenib induces ferroptosis in hepatocellular carcinoma by promoting TRIM54-mediated ubiquitination and degradation of FSP1 via the ERK pathway, with FSP1 reducing sorafenib sensitivity and enhancing tumor development. Here, AIFM2 is linked to hepatocellular carcinoma.